Clinical trials: 0800 023 4824 or 0207 0343341

Clinical trials specialists in the heart of London

Copyright © Heart Lung Centre Site Made With ♥️ By Gossh Expert 2xN

You can have a role in research that could change medicine forever.

Paid clinical research studies are being conducted at Heart Lung Centre to learn more about investigational medications that are not yet available to the public.

Are Clinical Trials safe?

This is a very important question. At Heart Lung Centre, all our trials are reviewed by an independent Research Ethics Committee, who ensure that our trials are as safe as possible. We are here to answer any questions.

 

Learn More

Do I get paid?

Our trials vary greatly in terms of time spent on the unit and the number of procedures performed. Once we have identified a suitable trial, we can inform you of the potential compensation for your participation.

 

Learn More

What facilities are there?

Whether you’re here for an hour or the whole day, we will endeavour to make your stay as comfortable as possible. The volunteer lounge will provide you with a space to pass the time pleasantly between assessments.

 

Why do you offer Clinical Trials?

Here at Heart Lung Centre we adhere to MHRA (The Medicines and Healthcare products Regulatory Agency) who are responsible for regulating the UK medical devices market. You can find out more information here.

VOLUNTEER REGISTRATION FORM 

Explore current trials to check eligibility and register

We are currently not running and do not have a license for phase I studies at this time.

We do not have any studies for healthy volunteers.

  • Asthma studies​

    Asthma Clinical Trials are to evaluate newly developed medications and new combinations of well-established medications for the treatment of asthma.

    For all studies, participants are paid for their time, travel and any inconvenience.

    Medications administered, trial or placebo would be in addition to a volunteer’s current medication(s).

    If you would like to find out more register your interest and we will be in touch. Or contact us on 0207 034 3341 or 0800 023 4824 or recruitment@heartlungcentre.com

    Current studies are detailed below.

  • Asthma Study D3250C00059

    This is a clinical trial to evaluate a newly developed anti-inflammatory medication for the treatment of Asthma against a placebo. The medication has been tested in previous clinical trials with volunteers with severe Asthma, no safety issues were reported and the medication was shown to significantly reduce exacerbation rates, improve lung function and symptoms.

    Any medication administered, trial or placebo would be in addition to your current medication(s). This study involves 11 to 13 visits to our central London clinic over 58 weeks. No over-night stays required.

    You will be paid up to £1650 (pro rata) for your time, and any inconvenience. Reasonable travel expenses will be reimbursed.

    To take part in this study you:

    • Must have been diagnosed with Asthma for 12 months or more
    • Must be between the ages of 18 to 70
    • Must use preventative Asthma medication on a stable, daily basis to manage your Asthma for at least 12 months
    • Must be a non-smoker or an ex-smoker for at least 12 months
    • Must not be, pregnant, lactating or trying to conceive with your partner. (If applicable)
    • Must not be currently enrolled another Clinical Trial

    If you believe you may be eligible to take part and would like to find out more, register your interest on /clinical-trials-request/ and we will be in touch. Or contact us to find out more on 0207 034 3341 or at recruitment@heartlungcentre.com .

    Even if you do not believe you may be eligible, do register your interest as new opportunities are pending.

    REGISTER

  • Asthma Study D7552C00001

    This is a randomized, double-blinded, placebo-controlled clinical trial to assess the efficacy and safety of AZD5718. No safety or tolerability issues linked to AZD5718 have yet been discovered in previous studies on healthy individuals.

    In total, there will be 6 visits, plus a telephone call, over a period of up to 5 months. You will be dispensed the study medication which you will have to consume two tablets in the morning daily alongside your regular asthma medication for 12 weeks.

    You will also be asked to fill out an e-diary and conduct spirometry measurements at home. Full training will be provided for this. The e-diary and spirometry measurements are to take place twice daily – in the morning after medication and in the evening.

    The study includes one initial screening visit to assess your eligibility. This includes questions about your medical history, a physical assessment, vital signs, ECGs, Blood tests and Lung Function testing. If you are found to be suitable there will be a second screening visit, where you will undergo further lung function tests, vital signs and blood tests. You will also be issued, and taught how to use, an at home spirometer and your e-dairy.

    You will be reimbursed for your Travel up to £50 for each visit. You will also be compensated £50 per visit for your time and inconvenience (£350 in total for the whole study.)

     To take part in this study you:

    • Must have been diagnosed with Asthma for 12 months or more
    • Must be between the ages of 18 to 70
    • Must use preventative Asthma medication on a stable, daily basis to manage your Asthma for at least 3 months
    • Must have an asthma exacerbation that required a dose of oral antibiotics or hospitalisation within the last 12 months
    • Must be a non-smoker or an ex-smoker for at least 6 months
    • Must not be, pregnant, lactating or trying to conceive with your partner. (If applicable)
    • Must not be currently enrolled another Clinical Trial

    If you believe you may be eligible to take part and would like to find out more, register your interest on /clinical-trials-request/ and we will be in touch. Or contact us to find out more on 0207 034 3341 or at recruitment@heartlungcentre.com .

    Even if you do not believe you may be eligible, do register your interest as new opportunities are pending.

    REGISTER

  • Asthma Study BP44551

    This is a randomized, double-blinded, placebo-controlled clinical trial to assess the safety of Selnoflast. No safety or tolerability issues linked to Selnoflast have yet been discovered in previous studies on healthy individuals. 

    In total, there will be 8 visits over a period of up to 11 weeks.

    You will be dispensed the study medication which you will have to consume one tablet in the morning (between 7-10am) and one in the evening (between 7-10pm) daily with food. You will take Selnoflast alongside your regular asthma medication for 11 weeks.

    You will also be asked to fill out an e-diary. Full training will be provided for this. (The e-diary are to take place twice daily – in the morning after medication and in the evening.)

    The study includes one initial screening visit to assess your eligibility. This includes questions about your medical history, a physical assessment, vital signs, ECGs, Blood tests and Lung Function testing.  If you are found to be suitable there will be a second screening visit, where you will undergo further lung function tests, vital signs and blood tests. You will also be issued, and taught how to use, an at your e-dairy.

    You will be reimbursed for your Travel up to £50 for each visit. You can be compensated up to £1200, or £1500 if you participate in the substudy, for your time and inconvenience for the whole study.

    To take part in this study you:

    • Must have been diagnosed with Asthma for 12 months or more
    • Must be between the ages of 18 to 80
    • Must use preventative Asthma medication on a stable, daily basis to manage your Asthma, for at least 3 months
    • Must be a non-smoker or an ex-smoker for at least 6 months
    • Must not be pregnant, lactating or trying to conceive with your partner.
    • Must not be currently enrolled another Clinical Trial

    If you believe you may be eligible to take part and would like to find out more, register your interest on /clinical-trials-request/ and we will be in touch. Or contact us to find out more on 0207 034 3341 or at recruitment@heartlungcentre.com .

    Even if you do not believe you may be eligible, do register your interest as new opportunities are pending.

    REGISTER

  • COPD studies​

    Chronic Obstructive Pulmonary Disease Clinical Trials are to evaluate newly developed medications and new combinations of well-established medications for the treatment of COPD.

    For all studies, participants are paid for their time, travel and any inconvenience.

    Medications administered, trial or placebo would be in addition to a volunteer’s current medication(s).

    If you believe you may be eligible to take part and would like to find out more, register your interest and we will be in touch. Or contact us to find out more on 0207 034 3341 or 0800 023 4824 or recruitment@heartlungcentre.com

    Current studies are detailed below.

  • COPD Study CLI – 06001AA1 – 04_05

    This is a clinical trial to evaluate a newly developed medication for the treatment of COPD - Chronic Obstructive Pulmonary Disease against a placebo. The CHF6001 Medication has been tested in previous trials with COPD volunteers. No safety issues have been reported in these studies and the medication has been well tolerated.

    Any medication administered, trial or placebo would be in addition to your current medications.

    To take part in this study you:

    • Must have been diagnosed with COPD for 12 months or more.
    • Must be aged 40 and above.
    • Must be a Smoker or an Ex-Smoker.
    • Must be using Inhaler(s) to manage your COPD.
    • Must have a history of COPD exacerbation(s) within the last 12 months.
    • Must Not be currently enrolled in another clinical trial.

     

    This study involves 6 to 7 short visits to our Central London clinic over 52 weeks. No over-night stays are required.

    You will be paid up to £1000, pro rata for your time, and any inconvenience. Reasonable travel expenses will be reimbursed.

    If you believe you may be eligible to take part and would like to find out more, register your interest and we will be in touch. Or contact us to find out more on 0207 034 3341 or 0800 023 4824 or recruitment@heartlungcentre.com

    Even if you do not believe you may be eligible, do register your interest as new opportunities are pending.

    REGISTER

  • COPD Study GB43311

    This is a Phase 2 clinical trial to evaluate the safety and efficacy of astegolimab at different dosages compared to a placebo in patients diagnosed with COPD. The drug has been well tolerated with no safety issues in previous trails.

    In total, there will be a maximum of 29 visits over up to 14 months, with an optional opportunity for this to extend an extra 17 visits that would add an additional 7 months.  There will be 1 Screening Visit, and once you are found to be suitable there will be up to 27 visits every 2 weeks for 1 year. This will be followed by a follow up visit. 

    At the screening visit your eligibility will be assessed. This will be done by filling in questionnaires, taking vital signs, urine, and blood samples, conducting lung function tests, CT scans, X rays and ECGs, and collecting Medical History. There is also an optional sub study where your sputum will be collected also if you opt in.                                             

    If you are found eligible, you will move onto the treatment visits, where the same assessments will be completed alongside being dosed with the study drug or placebo. The dosing method is 2 Subcutaneous injections of the medication in either side of the abdomen.

    To take part in this study you:

    • Must have been diagnosed with COPD for 12 months or more.
    • Must be aged between 40 and 90.
    • Must be a Smoker or an Ex-Smoker.
    • Must be using Inhaler(s) to manage your COPD.
    • Must have a history of two COPD exacerbation(s) that required the treatment of antibiotics and/or oral corticosteroids within the last 24 months.
    • Must not be currently enrolled in another clinical trial.

    You will be Reimbursed for your Travel for up to £50 for each visit.  This study does not reimburse for time. 

    If you believe you may be eligible to take part and would like to find out more, register your interest on /clinical-trials-request/ and we will be in touch. Or contact us to find out more on 0207 034 3341 or at recruitment@heartlungcentre.com .

    Even if you do not believe you may be eligible, do register your interest as new opportunities are pending.

    REGISTER

  • COPD Study D5988C00001

    This is a clinical trial to investigate the effect of a triple-acting inhaler (Breztri/Trixeo Aerosphere) compared to a dual-acting inhaler and a placebo on exercise tolerance and breathlessness in subjects with COPD, over the course of 14 weeks.

    Both the tri-acting and dual-acting inhalers are currently approved by the MHRA for the treatment of COPD and their safety profiles are well documented in this cohort.

    In total there will be 7 clinic visits and one follow up telephone phone call over a period of 14 weeks. 

    At the first screening, your eligibility will be assessed by carrying out various tests, including: an exercise test on a stationary bike to assess your current fitness level, vital signs, ECGs, lung function tests, urine blood sampling, and COPD relevant questionnaires. You will also be provided inhaler training to ensure your technique is optimal. The screening visit, and all subsequent visits, will last between 4 - 5 hours.

    If you are found eligible, you will move onto the treatment period of the study, where you will be treated with each of the triple-acting, dual-acting, and placebo inhalers separately across two-week periods, with two-week ‘washout’ periods in between, to ensure there isn’t any cross over from the drugs. After each two-week treatment period, you will be retested to measure the impact of the inhaler you’re currently using. You will also be provided with an electronic device for the duration of the study and will be asked to report your symptoms and medication use on a daily basis. Training on how to use this will be provided.

    You will be provided a study inhaler (Two puffs to be self-administered twice daily am/pm) to use throughout the study. It is important to note that you will be provided a placebo inhaler at some point in the study. Additionally, all maintenance inhalers would need to be stopped throughout the study duration, but you will be free to use Salbutamol/Ventolin as needed.

    You will be reimbursed for your travel up to £50 for each visit. If you believe your travel will cost more, with advance notice we can arrange the approvals for this.

    To take part in this study you:

    • Must have been diagnosed with COPD for 12 months or more.
    • Must be aged between 40 and 80.
    • Must be a Smoker or an Ex-Smoker.
    • Must be using Inhaler(s) to manage your COPD.
    • Must NOT have a history of a COPD exacerbation(s) that required the treatment of antibiotics and/or oral corticosteroids within the last 12 months.
    • Must not be currently enrolled in another clinical trial.

    If you believe you may be eligible to take part and would like to find out more, register your interest on /clinical-trials-request/ and we will be in touch. Or contact us to find out more on 0207 034 3341 or at recruitment@heartlungcentre.com .

    Even if you do not believe you may be eligible, do register your interest as new opportunities are pending.

    REGISTER

  • Chronic Cough

    For all studies, participants are paid for their time, travel and any inconvenience.

    Medications administered, trial or placebo would be in addition to a volunteer’s current medication(s).

    If you believe you may be eligible to take part and would like to find out more, register your interest and we will be in touch. Or contact us to find out more on 0207 034 3341 or 0800 023 4824 or recruitment@heartlungcentre.com

    Current studies are detailed below.

  • Chronic Cough Study GA43590

    This is a randomized, placebo-controlled, CROSSOVER, clinical trial to evaluate the efficacy and safety of GDC-G599 in patients with chronic refractory cough (secondary to asthma or COPD) or unexplained chronic cough. A previous phase I study on GDC-6599 showed no significant clinical, laboratory, or ECG findings.

    In total there will be 8 visits (10 days in clinic) during this study which take place over 12 weeks. This is a crossover study, so during the trial there will be a period where you receive a placebo and a period where you receive the active drug.

    The first visit will be a screening visit to determine eligibility. This will involve questions about your medical history, vital signs, ECG, a physical exam, urine tests, blood tests, lung function tests and a chest X-ray.

    If you are found to be suitable you will be asked to come back to the clinic to start the first treatment period. During this time, you will be asked to take the study medication (either placebo or active drug) twice a day for the next two weeks (or top of your usual medication) whilst coming to the clinic once a week for assessments.

    Once these two weeks have finished there will be a wash-out period of two weeks before you will be asked to come back to the clinic to start the second treatment period which will proceed in the same manner as the first, but you will be receiving the opposite treatment. After both treatment periods have been completed there will be one final follow-up visit.

    In this study you will be dispensed an e-diary with which to record your compliance when taking the study medication at home.  You will also be given a continuous cough monitoring device to use from the screening visit to the end of the second treatment period.  Full training for these devices will be provided by site staff.

    You will be Reimbursed for your Travel for up to £50 for each visit. You will also be reimbursed a total of £767 for your time and inconvenience over the course of the study.

    To take part in this study you:

    • Must have experienced a cough that persist despite treatment for 12 months or more
    • Must be between the ages of 18 to 80 (if you have unexplained chronic cough, or cough secondary to asthma), or 40+ (if you have cough secondary to COPD)
    • Must use preventative inhaler medication on a stable, daily basis to manage symptoms for at least 3 months
    • Must be a non-smoker or an ex-smoker
    • Must not be pregnant, lactating or trying to conceive with your partner.
    • Must not be currently enrolled another Clinical Trial

    If you believe you may be eligible to take part and would like to find out more, register your interest on /clinical-trials-request/ and we will be in touch. Or contact us to find out more on 0207 034 3341 or at recruitment@heartlungcentre.com .

    Even if you do not believe you may be eligible, do register your interest as new opportunities are pending.

    REGISTER

FAQ'S

If you want to know more about clinical trials or are considering participating in one, the following frequently asked questions describe the role of a patient and will help you understand this unique research program.

FAQ'S

Location

Explore beyond the Heart Lung Centre and discover Respiratory Clinical Trials and our hospital Queen Anne Street Medical Centre. Our state of the art facility offers a range of medical services, including consultants in different specialties, diagnostic tests and an operating theatre.

13-14 Fitzroy Square,
London, W1T 6AH

E: recruitment@heartlungcentre.com
P: 0800 023 4824
P: 0207 0343341

Give us a call or email us, we endeavour to answer all enquiries within 24 hours on business days.

We are open from 8am — 5pm week days.